What's Happening?
Lonza has announced the sale of its Capsules & Health Ingredients (CHI) business to Lone Star Funds for an enterprise value of CHF 2.3 billion ($3 billion). The transaction includes upfront cash proceeds of CHF 1.7 billion ($2.2 billion) for Lonza, which
will retain a 40% stake in the business. This move is part of Lonza's strategic shift to focus on its core business as a Contract Development and Manufacturing Organization (CDMO). The sale is expected to provide Lonza with significant cash for reinvestment and future growth opportunities. The CHI business, which returned to growth in 2025, is anticipated to continue its success under Lone Star's management, with Lonza benefiting from future value creation through its retained stake and preferential participation in exit proceeds.
Why It's Important?
The divestment of the CHI business marks a significant step in Lonza's transformation into a pure-play CDMO, allowing the company to concentrate on its strengths in pharmaceutical manufacturing. This strategic focus is likely to enhance Lonza's competitive position in the CDMO market, enabling it to better serve its clients and capitalize on emerging opportunities in complex and innovative pharmaceutical modalities. The transaction also highlights the growing trend of companies streamlining operations to focus on core competencies, which can lead to increased efficiency and profitability. For Lone Star, acquiring a leading business in the health ingredients sector presents an opportunity to expand its portfolio and leverage the business's established market presence. The deal's structure, with Lonza retaining a stake, suggests confidence in the CHI business's future performance and potential for value creation.
